Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Cardiac Arrhythmia
The Second Edition of this clinically oriented textbook about cardiac arrhythmia management continues to be a must-have volume for practicing cardiologists and internists, who require up-to-date information for the daily management of their patients. The material, prepared by recognized experts in the field, presents an in-depth look at diagnostic and treatment protocols in a readable, well-organized format. Unique chapters regarding pregnancy, athletes, and genetics also are included. A Brandon-Hill recommended title.
Progress in Drug Research
Nikolaus Seiler, Benoit Duranton and Francis Raul: The polyamine oxidase inactivator MDL 72527.- Zhi Hong and Craig E. Cameron: Pleiotropic mechanisms of ribavirin antiviral activities.- Jie Hong Hu and Charles Krieger: Protein phosphorylation networks in motor neuron death.- James O. Schenk: The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.- Laszlo Prokai: Central nervous system effects of thyrotropin-releasing hormone and ist analogues: opportunities and perspectives for drug discovery and development.- David F. Horrobin: A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E).- Suprabhat Ray, Reema Rastogi and Atul Kumar: Current status of estrogen receptors.
Pharmacological Aspects of Heart Disease
The importance of heart and artery disease as a cause of death and disability is difficult to exaggerate: it causes over half of all deaths in the western world and now accounts for one-quarter of deaths in the entire world. This appalling incidence persists in spite of commendable progress in treatment and prevention, particularly in the last two or three decades. Deaths from coronary disease have decreased by a third in the past twenty years and stroke has decreased by a half in the same period. This remarkable improvement, saving thousands of lives per year, has come about due to changes in life style (low fat diet, control of high blood pressure, less smoking and more exercise) and progress in treatment (more effective drugs, coronary care units, pacemakers, and cardiac surgery). Progress in understanding the pathophysiologic and pharn,acologic mechanisms operative in heart disease have been paramount in the development of more rational and more effective therapy. Dramatic and spectacular surgical treatments have fired the public imagination. Bypass surgery is commonplace and results in complete or considerable relief of symptoms in the majority of patients operated upon.
Heart Failure: A Companion to Braunwald's Heart Disease E-book
Dr. Douglas L. Mann, one of the foremost experts in the field, presents the 2nd Edition of Heart Failure: A Companion to Braunwald’s Heart Disease. This completely reworked edition covers the scientific and clinical guidance you need to effectively manage your patients and captures the dramatic advances made in the field over the last five years. Now in full color, this edition features eleven new chapters, including advanced cardiac imaging techniques, use of biomarkers, cell-based therapies and tissue engineering, device therapies, and much more. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Compatible with Kindle®, ...
Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques
Volume 36 of "Progress in Drug Research" contains 5 articles and the various indexes which facilitate its use and establish the connec tion with the previous volumes. While all articles deal with some of the topical aspects of drug research, the contribution by Robert R. Ruffolo et al. on "Drug receptors and control of the cardiovas cular system: Recent advances" is indeed in its own right a mono graphic presentation of this important domain. The remaining four reviews provide an overview of the work in volved in the search for new and better medicines, with a focus on chemical, pharmacological, toxicological, biological, biochemical and molecular modeling studies. In the 31 years this serie...
Current Catalog
First multi-year cumulation covers six years: 1965-70.
Congestive Heart Failure
This book is the first to approach the field of congestive heart failure as a true subspecialty of cardiology and cardiovascular surgery. The text discusses the entire field of congestive heart failure: the basic pathophysiologic mechanisms; the underlying diseases; the effects of heart failure on the remainder of circulation; the mechanisms and results of pharmacologic therapy; the multiple surgical and multidisciplinary approaches to end-stage heart disease; and the ultimate prognosis of congestive heart failure in all of the areas of heart failure management. Thus, this text uniquely puts into perspective all of the features of congestive heart failure and its management for the cardiologist, cardiovascular surgeon, and general internist.
Progress in Drug Research
Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].
